.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after an average follow-up of 11 months, people along with metastatic intestinal lumps who obtained biomarker-matched therapies based upon flowing growth DNA profiling revealed a more significant clinical benefit than those receiving unparalleled treatment.